Novartis announced that patients with Myelofibrosis initially randomized to treatment with Jakavi (ruxolitinib) lived longer than those randomized to treatment...
Background and objectives: Advocates for dementia-friendly communities emphasize the need for the public to know about the dementias and to experience social comfort with people having dementia.
Recro Pharma, Inc. announced the publication of new intravenous (IV) meloxicam data. The article, titled �Meloxicam intravenous for the treatment...
Recro Pharma, Inc. announced the publication of clinical data from its Phase III study evaluating the safety of intravenous (IV)...
Recro Pharma, Inc. announced a poster presentation highlighting intravenous (IV) meloxicam's effect on platelet function at the 72nd PostGraduate Assembly...